Trial Profile
Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Temozolomide (Primary) ; Dacarbazine; Fluorouracil
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 01 Nov 2018 Primary endpoint (Overall response rate) has been met, according to the results published in the Medicine
- 01 Nov 2018 Results published in the Medicine
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress